Related Experiment Videos

Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

N Eibl1, W Krugluger, G Streit

  • 1Rudolfstiftung Hospital, Vienna, Austria.

European Journal of Clinical Investigation
|March 18, 2004
PubMed

Insights

Improved metabolic control in type-2 diabetes patients significantly reduces platelet activation markers, suggesting a benefit in preventing vascular disease. This study highlights the link between better blood sugar management and healthier platelets.

Area of Science:

  • Endocrinology
  • Hematology
  • Cardiovascular Research

Background:

  • Cardiovascular disease is linked to platelet dysfunction in diabetic patients.
  • Hyperglycemia is a key risk factor for micro- and macrovascular complications.
  • Improved metabolic control shows promise for managing diabetic complications.

Purpose of the Study:

  • To investigate the impact of improved metabolic control on platelet activation markers in type-2 diabetes.
  • To clarify the relationship between hyperglycemia and platelet activation in diabetes.

Main Methods:

  • Studied 30 type-2 diabetes patients at baseline and after 3 months of improved metabolic control.
  • Compared platelet activation markers (CD31, CD36, CD49b, CD62P, CD63) using flow cytometry.
  • Included an age-matched nondiabetic control group.

Main Results:

  • Diabetic patients exhibited significantly higher platelet activation compared to controls.
  • Improvement in metabolic control led to a significant decrease in most platelet activation markers (except CD36).
  • A significant correlation was observed between CD62P, CD63, and HbA1c levels.

Conclusions:

  • Improved metabolic control exerts a beneficial effect on platelet activation in type-2 diabetes.
  • This finding suggests a potential role in mitigating the pathogenesis of vascular disease.
  • Better glycemic management may be crucial for cardiovascular health in diabetic individuals.
Abstract

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...